migraine
Conditions
Interventions
1.Sumatriptan succinate 50mg 2.Eletriptan hydrobronide 20mg 3.Naratriptan hydrochloride 2.5mg 4.Zolmitriptan 2.5mg 5.Rizatriptan benzoate 10mg Duration of treatment periods:8 weeks per a treatmen
Sponsors
School of pharmacy, Kitasato university
Kitasato Institute Hospital headache center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who are diagnosed with migraine according to the International Classification of Headache Disorders 2nd Edition(ICHD-II) 2)Patients who occur attacks of migraine 2 times or more per month 3)Triptan-naive patients or patients who don't determined a preference for triptans 4)Onset of migraine before the age of 50 years 5)Patients between 18 and 65 years of age 6)Both male and female patient 7)Patients who are provided informed,written consent for participation
Exclusion criteria
Exclusion criteria: 1)Patients with headache which is inability to distinguish between migraine and nonmigraine 2)Female who are pregnant or may be pregnant 3)Lactation 4)Patients with renal or hepatic impairment 5)Patients with history of myocardial infarction or with symptoms of ischemic heart disease 6)Patients with peripheral vascular disease 7)Patients with history of epileptiform attack or with brain disorder 8)Patients on monoamine oxidase inhibitors or within 2 weeks of discontinuation of monoamine oxidase inhibitors 9)Patients on HIV protease inhibitors 10)Hemodialysis patients 11)Patients on propranolol 12)Uncontrolled hypertension patients 13)Patients with psychiatric disorder which affect participation 14)Patients with hypersensitivity to any component of the study medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| #intensity of headache at 1 hour after taking the medication #intensity of headache at 2 hours after taking the medication #presence or absence of recurrence of migraine from 2 through 24 hours after taking the medication | — |
Secondary
| Measure | Time frame |
|---|---|
| #frequency of attacks #consumption of triptans per 8 weeks #consumption of nonsteroidal antiinflammatory drugs(NSAIDs) and other analgestics #HIT-6 scores | — |
Countries
Japan
Contacts
Public ContactKensuke Usui
School of pharmacy,Kitasato university Pharmacy practice and science Department of clinical pharmacy Center for clinical pharmacy and clini
Outcome results
None listed